Literature DB >> 15045627

Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis.

Iván Palomo1, Jaime Pereira, Marcelo Alarcón, Marcela Vásquez, Carmen Pinochet, María T Vélez, Jorge Sandoval, Gloria Icaza, Silvia Pierangeli.   

Abstract

Antiphospholipid antibodies (aPL) are a heterogeneous family of antibodies associated with thrombotic events and other complications. The objective of this study was to investigate the prevalence of aPL in a group of Chilean patients with thrombosis. Two hundred and twenty-six patients with venous and arterial thrombosis and 95 healthy controls were studied. Anticardiolipin (aCL), anti-beta(2 )glycoprotein I (anti-beta(2)GPI), and antiprothrombin (aPT) antibodies were determined. Eighty-eight out of 226 (38.9%) patients with thrombosis had some type of aPL. Fifty-seven patients (25.2%) were positive for aCL, 31 (13.7%) for aPT, and 14 (6.2%) for anti-beta(2)GPI antibodies. Twelve patients (5.3%) were positive for more than one aPL. IgG, IgM and IgA isotypes were observed in aCL, anti-beta(2)GPI, and aPT antibodies. Twenty-six out of 92 (28.3%) patients with venous thrombosis and 31/134 (23.1%) patients with arterial thrombosis were positive for aCL antibodies. With regard to the control group (4/95=4.2%), the odd ratios (OR) were 5.2 (1.3-19.8; p0.01) and 5.7 (1.6-22.3; p0.01), respectively. Additionally, we observed statistically significant OR with aPT and anti-beta(2)GPI antibodies; in the first, with venous and arterial thrombosis, and in the second, only with arterial thrombosis. Our results show a significant prevalence of aPL, predominantly aCL and aPT antibodies, in patients with thrombosis. Additionally, aCL and aPT antibodies appear to be a risk factor for venous and arterial thrombosis, and anti-beta(2)GPI antibodies appear to be a risk factor for arterial thrombosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15045627     DOI: 10.1007/s10067-003-0846-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

Review 1.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

2.  Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus.

Authors:  S S Lee; M L Cho; Y S Joo; W U Kim; Y S Hong; J K Min; S H Lee; S H Park; C S Cho; H Y Kim
Journal:  J Rheumatol       Date:  2001-03       Impact factor: 4.666

3.  Antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus.

Authors:  Ivan Palomo; Jaime Pereira; Marcelo Alarcon; Ana Maria Larrain; Carmen Pinochet; Marcela Vasquez; Maria T Velez; M Leon; Ricardo Espinola; Silvia Pierangeli
Journal:  J Lab Clin Med       Date:  2002-11

4.  [Anticardiolipin antibodies and early infarct of the myocardium].

Authors:  G Gaeta; S Lupoli; V Brancaccio; L Effuso; V Russo; A Boccalatte
Journal:  Cardiologia       Date:  1998-07

5.  Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases.

Authors:  S R Levine; M J Deegan; N Futrell; K M Welch
Journal:  Neurology       Date:  1990-08       Impact factor: 9.910

6.  beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program.

Authors:  R L Brey; R D Abbott; J D Curb; D S Sharp; G W Ross; C L Stallworth; S J Kittner
Journal:  Stroke       Date:  2001-08       Impact factor: 7.914

7.  Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus.

Authors:  A Montehermoso; R Cervera; J Font; M Ramos-Casals; M García-carrasco; F Formiga; J L Callejas; M Jorfán; M C Griñó; M Ingelmo
Journal:  Semin Arthritis Rheum       Date:  1999-04       Impact factor: 5.532

8.  Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis.

Authors:  V Eschwège; E Peynaud-Debayle; M Wolf; J Amiral; A M Vissac; F Bridey; M Dreyfus; C Boyer-Neumann; D Meyer
Journal:  Blood Coagul Fibrinolysis       Date:  1998-07       Impact factor: 1.276

9.  Antiphospholipid antibodies and venous thromboembolism.

Authors:  J S Ginsberg; P S Wells; P Brill-Edwards; D Donovan; K Moffatt; M Johnston; P Stevens; J Hirsh
Journal:  Blood       Date:  1995-11-15       Impact factor: 22.113

10.  Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.

Authors:  E Matsuura; Y Igarashi; T Yasuda; D A Triplett; T Koike
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  5 in total

1.  Val/Leu247 and Trp/Ser316 polymorphisms in beta 2 glycoprotein I and their association with thrombosis in unselected Chilean patients.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Marcela Vásquez; Carmen Pinochet; Fernando Poblete; Evelyn Mendez; Jeannette Sandoval; Rolando Vidal; Silvia Pierangeli
Journal:  Clin Rheumatol       Date:  2006-05-25       Impact factor: 2.980

2.  Prevalence of antiphospholipid antibodies in Chilean patients with rheumatoid arthritis.

Authors:  Iván Palomo; Carmen Pinochet; Marcelo Alarcón; Rodrigo Sandoval; Jaime Gonzalez; Francisco Monsalves; Ricardo Forastiero
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

3.  Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.

Authors:  Zurina Romay-Penabad; Maria Guadalupe Montiel-Manzano; Tuya Shilagard; Elizabeth Papalardo; Gracie Vargas; Arun B Deora; Michael Wang; Andrew T Jacovina; Ethel Garcia-Latorre; Elba Reyes-Maldonado; Katherine A Hajjar; Silvia S Pierangeli
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

4.  IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus.

Authors:  Tatiana Reshetnyak; Fariza Cheldieva; Maria Cherkasova; Alexander Lila; Evgeny Nasonov
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

5.  Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population.

Authors:  Chaojun Hu; Xi Li; Jiuliang Zhao; Qian Wang; Mengtao Li; Xinping Tian; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2020-10-05       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.